Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate

As with many first-generation antipsychotics (FGAs), zuclopenthixol and flupenthixol have no unique therapeutic benefit compared to other D2 antagonists, but have long-acting injectable (LAI) preparations available in certain parts of the world and a modest database of plasma level information. In addition to an LAI formulation, zuclopenthixol also has an injectable formulation (zuclopenthixol acetate) that provides therapeutic levels over several days, with a time to peak plasma levels (Tmax) of 24–48 hours [1].